Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730040 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT01730040 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 355 participants.
The verdict
NCT01730040, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).
Interventions
- DRUG Placebo
- DRUG Rosuvastatin
- DRUG Ezetimibe
- DRUG Alirocumab
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730040
The ClinicalTrials.gov registry entry for NCT01730040 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01730040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730040 about?
NCT01730040 is a clinical study titled "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)". This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).
What is the current status of trial NCT01730040?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2012-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01730040?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin (DRUG), Ezetimibe (DRUG), Alirocumab (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01730040?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.